Brief: Evelo Biosciences Announces Dosing Of First Patient In Phase 2 Trial Of Edp1815 In Atopic Dermatitis
17/02/2022 12:43
Feb 17 (Reuters) - Evelo Biosciences Inc EVLO.O :
* EVELO BIOSCIENCES ANNOUNCES DOSING OF FIRST PATIENT IN
PHASE 2
TRIAL OF EDP1815 IN ATOPIC DERMATITIS
Source text for Eikon: ID:nGNX4JlCjp
Further company coverage: EVLO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evelo Biosciences
See all newsU.S. RESEARCH ROUNDUP- Evelo Biosciences, Nkarta, O'Reilly Automotive
U.S. STOCKS ON THE MOVE-DXC Technology, Nvidia, Lisata Therapeutics
Evelo Bio slumps after skin disease drug fails in mid-stage study
U.S. STOCKS ON THE MOVE-Nvidia, Westlake, North American steel companies
U.S. STOCKS ON THE MOVE-TMC, PayPal, TOMI